Bupivacaine — research review 1

...and this brings us to bupivacaine, a long-acting local anesthetic often used in nerve blocks for pain relief. It acts by blocking sodium channels.

So, it’s effective for pain. But what’s the connection to aging and mortality that we're looking at today?

That’s a crucial question. The longevity thesis here isn't straightforward. While untreated chronic pain itself can accelerate biological aging – we see this, for instance, in painful diabetic neuropathy being linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy, according to GeroScience 2025 – the research on bupivacaine's long-term effects on aging and all-cause mortality is still developing.

So, it’s not simply a matter of treating pain equals slowing aging, then?

Precisely. Bupivacaine is definitely beneficial for appropriate, supervised pain management. But for long-term use, the evidence on its direct impact on biological aging markers like the epigenetic clock, or on all-cause mortality, isn't yet established. We don't have robust, long-term human studies that definitively link bupivacaine use to either accelerated or decelerated aging or changes in mortality risk.

That’s a significant gap. What about potential harms that might indirectly affect longevity?

Good point. With any local anesthetic, there are considerations like the risk of falls due to numbness or weakness, especially in older adults, and potential cardiovascular or neurological effects with systemic absorption, though these are typically managed in a clinical setting. But the specific, direct epigenetic effects on aging from bupivacaine itself, or its influence on all-cause mortality, remain areas where more research is needed.